within Pharmacolibrary.Drugs.ATC.C;

model C09XA02
  extends Pharmacokinetic.Models.PK_2C_enteral(
    weight         = 70,
    F              = 0.025,
    Cl             = 0.000825,
    adminDuration  = 600,
    adminMass      = 300 / 1000000,   // mg → kg
    adminCount     = 1,
    Vd             = 0.135,
    Cmin           = 0.001,
    Cmax           = 0.01,
    Ctox_peak      = 0.02,
    Ctox_trough    = 0.01,
    ka             = 0.005183333333333333,
    Tlag           = 22.8,            
    Vdp             = 0.383,
    k12             = 63.6,
    k21             = 63.6
    
  );

  annotation (Documentation(
    info       = "<html><body><table><tr><td>Drug:</td><td>C09XA02</td></tr><td>route:</td><td>oral</td></tr><tr><td>n-compartments</td><td>2</td></tr></table><p>Aliskiren is a direct renin inhibitor used primarily for the treatment of hypertension. It reduces plasma renin activity and lowers blood pressure. Aliskiren is approved for clinical use in several countries, though its usage may be limited due to safety concerns in some specific patient populations.</p><h4>Pharmacokinetics</h4><p>Reported values in healthy adult subjects after single oral administration.</p><h4>References</h4><ol><li><p>Buczko, W, &amp; Hermanowicz, JM (2008). Pharmacokinetics and pharmacodynamics of aliskiren, an oral direct renin inhibitor. <i>Pharmacological reports : PR</i> 60(5) 623–631. PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/19066408/\">https://pubmed.ncbi.nlm.nih.gov/19066408</a></p></li><li><p>Vaidyanathan, S, et al., &amp; Dole, WP (2007). Pharmacokinetics of the oral direct renin inhibitor aliskiren alone and in combination with irbesartan in renal impairment. <i>Clinical pharmacokinetics</i> 46(8) 661–675. DOI:<a href=\"https://doi.org/10.2165/00003088-200746080-00003\">10.2165/00003088-200746080-00003</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/17655373/\">https://pubmed.ncbi.nlm.nih.gov/17655373</a></p></li><li><p>Dieterle, W, et al., &amp; Mann, J (2004). Effect of the oral renin inhibitor aliskiren on the pharmacokinetics and pharmacodynamics of a single dose of warfarin in healthy subjects. <i>British journal of clinical pharmacology</i> 58(4) 433–436. DOI:<a href=\"https://doi.org/10.1111/j.1365-2125.2004.02160.x\">10.1111/j.1365-2125.2004.02160.x</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/15373937/\">https://pubmed.ncbi.nlm.nih.gov/15373937</a></p></li></ol></body></html>",
    revisions  = "<html><body><ul><li>06/2025 initial model generated by LLM gpt-4.1 from general data</li></ul></body></html>"
  ));
end C09XA02;
